As the recent approval of the EGFR and ALK inhibitors for the treatment of NSCLC, research has focused on the use of preclinical models and tissue biopsies from patients to examine the mechanisms of responsiveness and resistance to these molecules or to emerging targeted agents 11,19. The gene discussed is ALK; the disease is non-small cell lung carcinoma.